Relative risk of conversion to an elevated PSA between baseline and year 4 using 4 and 6 ng/mL cutoff points
| Cut point (ng/mL) | Placebo (n = 263), n cases (%) | Calcium (n = 279), n cases (%) | Risk ratio (95% CI) |
|---|---|---|---|
| >4 | 21 (8) | 14 (5) | 0.63 (0.33-1.21) |
| >6 | 13 (5) | 10 (4) | 0.73 (0.32-1.63) |
NOTE: PSA concentration determined at both baseline and year 4 for 263 men assigned to the placebo group and 279 to the calcium group.